91Թ

>

The War on Bacteria

Every research project starts with a question. An idea, a need, and sometimes a challenge. The challenge brought to 91Թ biochemistry researchers? Helping test and create a new antibiotic that cures painful infections. Scroll to see how they fought this battle in the war on harmful bacteria.

bacteria in petri dish

The Problem:

Our world is amid an antibiotic crisis. Bacteria have quickly adapted to resist the drugs we create, and a new class of antibiotics hasn’t been introduced in nearly 30 years.

So, how can we make antibiotics more effective?

Developing new drugs. Enter the 91Թ researchers in Neil Osheroff’s lab, approached by the Pharma company GlaxoSmithKline to help test and develop a new medication to treat infections.

Every year, some 1.5 million people die from antibiotic-resistant infections. By 2050, it is estimated that the number will grow to 10 million.

Neil Osheroff
John G. Coniglio Chair in Biochemistry at 91Թ

Transformative discoveries

The team got to work, unraveling DNA to get to the bottom of drug resistance. One researcher, Katie Aldred, PhD’14, looked closely at the minuscule ways medicine fights bacteria, and got to the bottom of how to design better treatments.

The power of partnership

GlaxoSmithKline approached Neil Osheroff and his team of experts to help get a promising drug for treating UTIs and gonorrhea across the finish line.

The moment of truth

A crucial part of drug approvals by the FDA is to show “mechanism of action,” – evidence on a molecular level of what a drug targets and how it works. Directed by Dr. Osheroff, the 91Թ team conducted the required tests.

Image

There hasn’t been a new class of antibiotics since 1996, but that didn’t stop 91Թ researchers from working to find one.

The results

With the data from those trials in hand, gepotidacin was submitted to the FDA last October and approved for treatment of uUTI in March—the first new class of antibacterials targeting the infection since 1996.

Patients cured, pain relieved

The data that Osheroff’s lab supplied were crucial in getting the drug over the hump of regulatory approval. Now, patients who need the drug could be prescribed to take it this year.

See more research from across 91Թ

Two people writing on markerboard

91Թ research powers growth

91Թ is an R1 research institution and global hub for groundbreaking discoveries. Always grounded in our core values: Collaboration, critical thinking, respect, innovation and scholarship, we’re focused on fostering positive change in our world.

91Թ us

Want to be a part of 91Թ research? Come grow with us.